Pfizer (PFE) heads into Monday's trading session with a significantly heavier oncology news load than its share price reflected last week, following the release of fresh data at the American Society of Clinical Oncology (ASCO) meeting and a major partnership in China valued at up to $10.5 billion.
The timing is critical. U.S. markets were closed on Sunday, and the previous week was shortened by the Memorial Day holiday on Monday, meaning Monday's regular session from 9:30 a.m. to 4 p.m. ET will be the first full market test of the weekend's ASCO data.
Pfizer closed Friday at $26.18, up just 0.15%, and finished the holiday-shortened week approximately 1.1% above its May 22 close of $25.90. In comparison, the S&P 500 ETF gained 0.24% on Friday, while the Health Care Select Sector SPDR ETF fell 0.89%. Among large pharmaceutical peers, Eli Lilly lost 1.93%, Merck fell 0.98%, and Bristol Myers Squibb rose 0.49%.
The stock's muted movement belies the significance of the underlying news. Pfizer is striving to convince investors it has a sustainable growth story after the pandemic-era surge in COVID products waned and as patent expirations pressure older drugs. The company expects stronger growth after 2028, driven by obesity drugs in development, cancer medicines, Vyndamax patent protection, and a favorable European court ruling on COVID vaccine purchases.
The most immediate readout came Sunday from Braftovi in a genetic subtype of metastatic colorectal cancer. Pfizer reported that the regimen nearly doubled progression-free survival — the time patients live without the cancer worsening — to 15.2 months from 8.3 months in the comparator arm, and reduced the risk of death by 44%. Scott Kopetz of MD Anderson, co-principal investigator of the trial, said the results “strengthen confidence” in treatment for this patient group.
Earlier, Pfizer announced that Talzenna plus Xtandi reduced the risk of radiographic progression or death by 52% in metastatic prostate cancer with certain DNA-repair gene changes. Neeraj Agarwal of Huntsman Cancer Institute, the trial's global lead investigator, described the result as “durable disease control,” though overall survival data remain interim. Additionally, seven-year Lorbrena data in ALK-positive advanced non-small cell lung cancer showed 55% of patients remained alive without disease progression at seven years. Tony Shu-Kam Mok of the Chinese University of Hong Kong called the outcomes “remarkable” and a “fundamental shift” for expectations in that disease.
Beyond ASCO, Pfizer and Innovent Biologics announced a 12-program oncology collaboration covering antibody-drug conjugates (ADCs) and multi-specific antibodies. Innovent will receive $650 million upfront and up to $9.85 billion in milestone payments. Jeff Legos, Pfizer's chief oncology officer, said the companies aim to “move faster, go further.”
Investors have heard similar pitches before. In Pfizer's first-quarter release, CEO Albert Bourla highlighted pipeline progress in oncology and obesity, while CFO David Denton pointed to 22% operational revenue growth from launched and acquired products. Revenue stood at $14.45 billion, and Pfizer reaffirmed 2026 revenue guidance of $59.5 billion to $62.5 billion. However, analysts remain cautious. J.P. Morgan's Chris Schott noted that investors need more clinical data and lower risk around pipeline programs before sentiment improves, while RBC Capital's Trung Huynh described Pfizer as a “catalyst story, not an earnings story.”
The week ahead keeps oncology in focus. Pfizer's ASCO schedule includes Monday presentations in breast and gynecological cancers, and a Tuesday oral presentation on tucatinib as maintenance therapy in HER2-positive metastatic breast cancer. While not every abstract moves a stock, investors now have enough data to reassess the pipeline debate.
Yet the risks are clear. Some data are interim or early, several programs still require regulatory approval and commercial uptake, and the Innovent assets are early-stage medicines that must clear Phase 1 trials. Pfizer's own disclosure on the Innovent deal flagged closing risk, uncertain clinical endpoints, regulatory questions, and the possibility that expected benefits are not realized. For now, Pfizer's share price is not trading like a breakout, but Monday's open will reveal whether the weekend's substance is enough to shift sentiment.
